ArticleMolecular pharmacology2025
Effects of two structurally diverse positive allosteric modulators on signaling bias at the μ-opioid receptor.
Article in Molecular pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The μ-opioid receptor (MOR) is responsible for the analgesic actions of opioid drugs as well as their unwanted actions, including respiratory depression and addiction liability. Following agonist occupancy, MOR can signal via G-protein and/or β-arrestin. However, MOR agonists may show an imbalance between activating these 2 pathways. Evidence from studies of G-protein-coupled receptors suggests that allosteric modulators can influence agonist signaling profiles. However, no studies have examined this phenomenon at MOR. In this study, we compare the ability of various orthosteric MOR agonists to activate G-protein or recruit β-arrestin in the absence or presence of 2 structurally distinct MOR positive allosteric modulators, BMS-986187 (a xanthenedione) or BMS-986122 (a thiazolidine). We determined the potency and efficacy of 6 orthosteric agonists (DAMGO, fentanyl, methadone, morphine, Met-enkephalin, and SR17018) with and without BMS-986187 or BMS-986122, and determined bias factors for the agonists themselves and in the presence of a modulator. The 2 allosteric modulators enhanced the potency of agonists to different degrees showing probe dependence and differentially shifted the ability of agonists to activate G-protein as compared to recruitment of β-arrestin, indicating an effect on ligand bias. In both measures, in the presence of either modulator, the higher efficacy agonists showed a shift in potency. In contrast, lower efficacy compounds showed an increase in maximal effect with a smaller shift in potency. Overall, the studies provide evidence that positive allosteric modulators influence the degree and direction by which orthosteric agonists signal downstream of MOR. SIGNIFICANCE STATEMENT: Biased agonism and positive allosteric modulation at the μ-opioid receptor have been suggested as approaches to improve the therapeutic index of opioid agonists. This work shows how allosteric modulation alters the bias signaling profile of μ-opioid agonists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.